Kohl's Corporation vs Zoetis Inc — how do they compare? Kohl's Corporation trades at $19.24 (market cap $2.10B), while Zoetis Inc trades at $73.83 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 14.8× Kohl's Corporation's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| KSS | ZTS | |
|---|---|---|
Market Cap | $2.10B | $31.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $156.76 |
52-Week Low | $11.72 | $71.91 |
Enterprise Value | $8.20B | $38.70B |
Dividend Yield | 2.7% | 2.81% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Trailing returns across standard periods
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →